Remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, has shown efficacy and favourable safety in the REMIX-1/2 studies in patients with chronic spontaneous urticaria (CSU). Herein, we report the impact of remibrutinib treatment on Work Productivity and Activity Impairment (WPAI) and Dermatology Life Quality Index (DLQI) outcomes. REMIX-1 and REMIX-2 were identical, phase III,… →

Recruiting clinical trial participants to time and target can be challenging. Innovative recruitment strategies, such as facilitating participant self-referral, can be beneficial. The BEACON trial is a national multicentre phase IV assessor-blinded randomized controlled trial comparing the effectiveness, tolerability and cost-effectiveness of ciclosporin, methotrexate and dupilumab in adults with moderate-to-severe eczema. The aim of this… →

The aim of this study was to test whether a weekly bath or shower improves eczema symptoms compared with a daily bath or shower for people with eczema. This was an online, pragmatic, superiority randomized controlled trial, codesigned by people with eczema (citizen scientists), healthcare professionals and researchers. The Eczema Bathing Study is the first… →

Amlitelimab is a fully human, nondepleting anti-OX40 ligand (OX40L) monoclonal antibody under investigation for atopic dermatitis (AD). Lesions on the head and neck are difficult to treat due to multiple triggers and generally have lower response to treatments than lesions observed in other body regions. Here we report the impact of amlitelimab on Eczema Area… →

Treatment options for moderate-to-severe alopecia areata (AA) have limited efficacy. Methotrexate, a conventional immunosuppressant, has been used for AA, while Janus kinase inhibitors like tofacitinib have shown promising results. Our aim was to compare the efficacy and safety of oral tofacitinib and methotrexate in treating moderate-to-severe AA. This study recruited 36 patients with moderate-to-severe AA,… →

Treatment options for moderate-to-severe alopecia areata (AA) have limited efficacy. Methotrexate, a conventional immunosuppressant, has been used for AA, while Janus kinase inhibitors like tofacitinib have shown promising results. Our aim was to compare the efficacy and safety of oral tofacitinib and methotrexate in treating moderate-to-severe AA. This study recruited 36 patients with moderate-to-severe AA,… →

CONCLUSION: Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI. →

CONCLUSIONS: Both the ISO-SR and ISO-MR exercises to volitional fatigue reduced pain sensitivity in patients with knee osteoarthritis. Neither exercise volume changed clinical pain intensity. →

CONCLUSION: Based on the results of the study, education based on the Health Belief Model has been effective in improving sexual self-care and enhancing the constructs of the model in women with human papillomavirus (HPV). Therefore, it is recommended that this theory be considered by healthcare providers and midwives when educating patients with human papillomavirus. →